Viking Global Investors LP Bristol Myers Squibb CO Transaction History

Viking Global Investors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $112 Million - $134 Million	-1,815,619 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $279 Million - $326 Million	-5,207,645 Reduced 74.15%	1,815,619 $113 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $254 Million - $298 Million	-4,294,488 Reduced 37.94%	7,023,264 $416 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $379 Million - $413 Million	6,122,279 Added 117.84%	11,317,752 $756 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $160 Million - $179 Million	2,688,680 Added 107.26%	5,195,473 $328 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $39.4 Million - $44.7 Million	-682,471 Reduced 21.4%	2,506,793 $155 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $183 Million - $203 Million	3,189,264 New	3,189,264 $192 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.